InvestorsHub Logo
Followers 155
Posts 2647
Boards Moderated 0
Alias Born 01/29/2004

Re: tredenwater2 post# 335760

Thursday, 11/11/2021 6:42:31 PM

Thursday, November 11, 2021 6:42:31 PM

Post# of 462582
Improved Biochemistries

Ain't this (statistically) just great:

"“We now have robust and concordant data that ADUHELM has effect on two core defining pathologies of Alzheimer’s disease, and substantial evidence of treatment correlation between changes in plasma p-tau181 and the slowing of disease progression,” said Alfred Sandrock, Jr., M.D., Ph.D., Head of Research and Development at Biogen."

But, can the people taking the drug now actually think better?

And, how long will those putatively improved biochemistries persist? A short or long term fix (if anything functional at all)?

Some meager (but 'precise') molecular data. Great. Now, let's learn of the actual functional, behavioral benefits (if any).

Who's gonna show those first for Alzheimer's? Anavex or Biogen?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News